InflaRx (IFRX) Long-Term Investments (2017 - 2026)
InflaRx (IFRX) posted Long-Term Investments of $9.7 million for Q1 2026, up 3401.34% sequentially from $276312.5 in Q4 2025, and down 47.94% YoY from $18.6 million in Q1 2025.
InflaRx (IFRX) Long-Term Investments (2017 - 2026) Analysis & Trends
InflaRx has reported Long-Term Investments for 10 years, with the latest figure at $9.7 million in Q1 2026.
- Quarterly Long-Term Investments fell 47.94% year-over-year to $9.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.7 million (down 47.94% YoY) and the FY2025 annual result came in at $55.9 million, down 41.18% from the prior year.
- Long-Term Investments improved to $9.7 million in Q1 2026 per IFRX's latest filing, from $276312.5 in the prior quarter.
- Over five years, Long-Term Investments peaked at $8553.5 billion in Q1 2023 and troughed at $276312.5 in Q4 2025.
- A 5-year average of $777.6 billion and a median of $45.7 million in 2025 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2023 and 2024: Long-Term Investments jumped 3042.29% in 2023, then tumbled 96.45% in 2024.
- Over 5 years, Long-Term Investments stood at $3.0 million in 2022, then soared by 3042.29% to $93.0 million in 2023, then sank by 96.45% to $3.3 million in 2024, then plunged by 91.64% to $276312.5 in 2025, then jumped by 3401.34% to $9.7 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $9.7 million, $276312.5, and $45.7 million for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.67 Mn |
| Dec 31, 2025 | 276,312.50 |
| Jun 30, 2025 | 45.73 Mn |
| Mar 31, 2025 | 18.58 Mn |
| Dec 31, 2024 | 3.30 Mn |
| Jun 30, 2024 | 59.98 Mn |
| Dec 31, 2023 | 93.00 Mn |
| Jun 30, 2023 | 109.65 Mn |
| Mar 31, 2023 | 8,553.54 Bn |
| Dec 31, 2022 | 2.96 Mn |
| Jun 30, 2022 | 89.95 Mn |
| Dec 31, 2021 | 31.12 Mn |
| Sep 30, 2021 | 31,505.85 Bn |
| Dec 31, 2020 | 324,622.37 |
| Sep 30, 2020 | 318.24 Mn |
| Jun 30, 2020 | 300.29 Mn |
| Mar 31, 2020 | 301,064.04 |
| Dec 31, 2019 | -83,617.62 |
| Sep 30, 2019 | 303,490.44 |
| Jun 30, 2019 | 325,855.34 |